MedPath

the association between Ki67 and clinical features in patients with advanced EGFR-positive lung adenocarcinoma

Not Applicable
Conditions
40 cases diagnosed advanced lung adenocarcinoma. The 20 cases were EGFR mutation positive and treated with EGFR inhibitors, and the other 20 cases are EGFR mutation negative and treated with chemotherapy and/or immunotherapy.
Registration Number
JPRN-UMIN000042886
Lead Sponsor
Tohoku Medical and Pharmaceutical University,Tohoku Medical and Pharmaceutical University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

Patients having an overlap cancer with activity Patients that an doctor judged to be inappropriate.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
We measure the staining intensity of Ki67 in EGFR-positive and EGFR-negative cases, and examine the effect with EFGR inhibitors and prognosis of according to the intensity of Ki67 in EGFR-positive cases.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath